Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions,
rewards, and special promotions.
Unfortunately, the antibody (ID:147650) is no longer available.
Below is a list of antibodies to the same protein target. You may also try your search again using the search box at the top of the page.
Please contact us if you have any questions.
TNC / Tenascin C
Tenascin C (TNC) is the founding member of the gene family. In the embryo it is made by migrating cells like the neural crest; it is also abundant in developing tendons, bone and cartilage. The basic structure is 14 EGF-like repeats towards the N-terminal end, and 8 or more fibronectin-III domains which vary upon species and variant. TNC has anti-adhesive properties, causing cells in tissue culture to become rounded after it is added to the medium. One mechanism to explain this may come from its ability to bind to the extracellular matrix glycoprotein fibronectin and block fibronectin's interactions with specific syndecans. The expression of tenascin-C in the stroma of certain tumors is associated with a poor prognosis.
Involvement of large tenascin-C splice variants in breast cancer progression. Tsunoda T, Inada H, Kalembeyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T. The American journal of pathology. 2003 162:1857-67.
Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T. The American journal of pathology. 2005 167:71-80.
Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. Kriinen E, Nummela P, Soikkeli J, Yin M, Lukk M, Jahkola T, Virolainen S, Ora A, Ukkonen E, Saksela O, Hltt E. The Journal of pathology. 2006 210:181-91.
Expression of large tenascin-C splice variants by hepatic stellate cells/myofibroblasts in chronic hepatitis C. El-Karef A, Kaito M, Tanaka H, Ikeda K, Nishioka T, Fujita N, Inada H, Adachi Y, Kawada N, Nakajima Y, Imanaka-Yoshida K, Yoshida T. Journal of hepatology. 2007 46:664-73.
B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?. Richter P, Tost M, Franz M, Altendorf-Hofmann A, Junker K, Borsi L, Neri D, Kosmehl H, Wunderlich H, Berndt A. Journal of cancer research and clinical oncology. 2009 135:1351-8.
Increased presence of stromal myofibroblasts and tenascin-C with malignant progression in canine mammary tumors. Yoshimura H, Michishita M, Ohkusu-Tsukada K, Takahashi K. Veterinary pathology. 2011 48:313-21.
Expression of tenascin-C and its isoforms in the breast. Guttery DS, Shaw JA, Lloyd K, Pringle JH, Walker RA. Cancer metastasis reviews. 2010 29:595-606.
A migration signature and plasma biomarker panel for pancreatic adenocarcinoma. Balasenthil S, Chen N, Lott ST, Chen J, Carter J, Grizzle WE, Frazier ML, Sen S, Killary AM. Cancer prevention research (Philadelphia, Pa.). 2011 4:137-49.
Regeneration of the perineurium after microsurgical resection examined with immunolabeling for tenascin-C and alpha smooth muscle actin. Yamamoto M, Okui N, Tatebe M, Shinohara T, Hirata H. Journal of anatomy. 2011 218:413-25.
Novel effects of CCN3 that may direct the differentiation of chondrocytes. Janune D, Kubota S, Nishida T, Kawaki H, Perbal B, Iida S, Takigawa M. FEBS letters. 2011 585:3033-40.
Promoting effects of carminic acid-enriched cochineal extracts on capsular invasive thyroid carcinomas through targeting activation of angiogenesis in rats. Kemmochi S, Shimamoto K, Shiraki A, Onda N, Hasumi K, Suzuki K, Mitsumori K, Shibutani M. The Journal of toxicological sciences. 2012 37:475-82. (IHC; Rat)
Lac color inhibits development of rat thyroid carcinomas through targeting activation of plasma hyaluronan-binding protein. Kemmochi S, Yamamichi S, Shimamoto K, Onda N, Hasumi K, Suzuki K, Mitsumori K, Shibutani M. Experimental biology and medicine (Maywood, N.J.). 2012 237:728-38. (IHC; Rat)
Direct progression of capsular invasive carcinomas from subcapsular focal hyperplasias induced by hypothyroidism-mediated tumor promotion in a rat two-stage thyroid carcinogenesis model. Ago K, Kemmochi S, Morita R, Yafune A, Shiraki A, Mitsumori K, Shibutani M. Journal of cancer research and clinical oncology. 2013 139:395-401. (IHC; Rat)